GlassScriptPhysician profile
Sirus Farivar
NPI 1891896841
$2,943.96
in general payments reported to CMS, 2019-2025
21 companies · $497 in 2025
The $497 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $414 · 2021: $673 · 2022: $244 · 2023: $180 · 2024: $633 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280 · Education: $30.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.67 |
| Education | $30.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $673.55 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $407.90 | 2022-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $292.36 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $232.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $178.07 | 2021-2023 | Entyvio |
| Gilead Sciences, INC. | $161.63 | 2019-2020 | |
| Genzyme Corporation | $129.77 | 2022-2024 | |
| Allergan, INC. | $127.43 | 2019 | |
| Phathom Pharmaceuticals, INC. | $115.05 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $111.92 | 2024-2025 | Vegzelma, Zymfentra |
| Abbvie INC. | $104.27 | 2021 | |
| Madrigal Pharmaceuticals | $81.89 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $71.32 | 2022-2024 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $59.29 | 2025 | Iqirvo |
| Lilly USA, LLC | $51.93 | 2025 | Omvoh |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $40.44 | 2019 | |
| Ironwood Pharmaceuticals, INC | $27.44 | 2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $22.63 | 2021 | |
| Endogastric Solutions, INC | $22.04 | 2023 | Esophyx |
| Endo Pharmaceuticals INC. | $19.33 | 2019 | |
| W. L. Gore & Associates, INC. | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sirus Farivar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.